Logo

AbbVie Submits Regulatory Applications to the US FDA and EMA for Rinvoq (upadacitinib) to Treat Atopic Dermatitis

Share this

AbbVie Submits Regulatory Applications to the US FDA and EMA for Rinvoq (upadacitinib) to Treat Atopic Dermatitis

Shots:

  • The company submitted applications to the US FDA & EMA seeking approval for Rinvoq (upadacitinib) for adults (15mg/30mg- qd) and adolescents (15mg- qd) with moderate to severe AD. The submission is based on three pivotal P-III studies and was studied without TCS in Measure Up 1 and Measure Up 2 and with TCS in AD Up
  • Results: Rinvoq demonstrated an improvement in skin clearance and reduction in itch in adults and adolescents- met its co-1EPs including at least a 75% improvement in EASI 75 and a validated (vIGA-AD) score of 0/1 @16wks.- no new safety profile in observed
  • Rinvoq is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. The submissions reinforce AbbVie's commitment to bringing Rinvoq to more patients living with immune-mediated diseases

 ­ Ref: Abbvie | Image: abbvie

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions